Details for New Drug Application (NDA): 201914
✉ Email this page to a colleague
The generic ingredient in RIZATRIPTAN BENZOATE is rizatriptan benzoate. There are twenty-two drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the rizatriptan benzoate profile page.
Summary for 201914
Tradename: | RIZATRIPTAN BENZOATE |
Applicant: | Glenmark Pharms Ltd |
Ingredient: | rizatriptan benzoate |
Patents: | 0 |
Pharmacology for NDA: 201914
Mechanism of Action | Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists |
Suppliers and Packaging for NDA: 201914
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
RIZATRIPTAN BENZOATE | rizatriptan benzoate | TABLET, ORALLY DISINTEGRATING;ORAL | 201914 | ANDA | Glenmark Pharmaceuticals Inc., USA | 68462-467 | 68462-467-06 | 6 BOX in 1 CARTON (68462-467-06) / 3 POUCH in 1 BOX (68462-467-46) / 1 BLISTER PACK in 1 POUCH / 1 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK |
RIZATRIPTAN BENZOATE | rizatriptan benzoate | TABLET, ORALLY DISINTEGRATING;ORAL | 201914 | ANDA | Glenmark Pharmaceuticals Inc., USA | 68462-467 | 68462-467-74 | 4 BOX in 1 CARTON (68462-467-74) / 3 POUCH in 1 BOX / 1 BLISTER PACK in 1 POUCH / 1 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, ORALLY DISINTEGRATING;ORAL | Strength | EQ 5MG BASE | ||||
Approval Date: | Jul 1, 2013 | TE: | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, ORALLY DISINTEGRATING;ORAL | Strength | EQ 10MG BASE | ||||
Approval Date: | Jul 1, 2013 | TE: | RLD: | No |
Complete Access Available with Subscription